AM-1638 is primarily utilized in research settings, particularly in the field of pharmacology and drug development. It functions as a selective agonist for the free fatty acid receptor 1 (FFAR1), also known as GPR40. This receptor plays a significant role in glucose-stimulated insulin secretion, making AM-1638 a valuable compound for studying potential treatments for type 2 diabetes. Researchers use it to explore mechanisms of insulin release and to evaluate its efficacy in improving glucose homeostasis. Additionally, AM-1638 aids in understanding the signaling pathways associated with FFAR1, contributing to the development of novel therapeutic agents targeting metabolic disorders. Its application extends to preclinical studies, where it helps assess the safety and effectiveness of new diabetes-related drugs.